α1 - Antitrypsin deficiency 5: Intravenous augmentation therapy: current understanding

Stoller, J. K.; Aboussouan, L. S.
August 2004
Thorax;Aug2004, Vol. 59 Issue 8, p708
Academic Journal
The biochemical and clinical efficacy of intravenous augmentation therapy in α1 -antitrypsin deficiency is reviewed, adverse events experienced with this treatment are considered, and its cost effectiveness is discussed.


Related Articles

  • Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human α1-antitrypsin. Piitulainen, Eeva; Bernspång, Elisabeth; Björkman, Sven; Berntorp, Erik // European Journal of Clinical Pharmacology;Jun2003, Vol. 59 Issue 2, p151 

    Objective. Severe α1-Antitrypsin (AAT) deficiency (PiZZ) predisposes to the development of emphysema. Intravenous augmentation therapy with purified human AAT has been available since 1988. The dosage has varied from 60 mg/kg body weight once weekly to 250 mg/kg once monthly. We have found...

  • 728. Safety and Bioactivity of rAAV2-hAAT in alpha-1 Antitrypsin-Deficient Patients in a Phase I Clinical Trial. Brantly, Mark L.; Spencer, Terry; Spencer, Carolyn T.; Conlon, Thomas J.; Sihong Song; Humphries, Margaret; Byrne, Barry J.; Snyder, Richard O.; Flotte, Terence R. // Molecular Therapy;Jun2006, Vol. 13, pS281 

    INTRODUCTION: Recombinant adeno-associated virus (rAAV) vectors are capable of sustained expression of therapeutic proteins when administered to skeletal muscle. A single injection of a rAAV2 vector in mice resulted in sustained secretion of human alpha-1 antitrypsin (hAAT) at levels that would...

  • PICTURE QUIZ.  // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;2/6/2010, Vol. 340 Issue 7741, p312 

    A picture quiz about a chest radiograph of a patient with antitrypsin deficiency is presented.

  • On the probability of cost-effectiveness using data from randomized clinical trials. Willan, Andrew R. // BMC Medical Research Methodology;2001, Vol. 1, p8 

    Background: Acceptability curves have been proposed for quantifying the probability that a treatment under investigation in a clinical trial is cost-effective. Various definitions and estimation methods have been proposed. Loosely speaking, all the definitions, Bayesian or otherwise, relate to...

  • Dementia case management effectiveness on health care costs and resource utilization: a systematic review of randomized controlled trials. PIMOUGUET, C.; LAVAUD, T.; DARTIGUES, J. F.; HELMER, C. // Journal of Nutrition, Health & Aging;Aug2010, Vol. 14 Issue 8, p669 

    The growing number of dementia patients leads to both policy, economic and health organization constraints. Many healthcare systems have developed case management programs in order to optimize dementia patients and caregivers care and services delivery. Nevertheless, to what extend case...

  • The pathway to physician reimbursement for cardiac implantable electronic devices (CIEDs): a history and brief synopsis. Roka, Attila; Schoenfeld, Mark // Journal of Interventional Cardiac Electrophysiology;Mar2013, Vol. 36 Issue 2, p137 

    Cardiac implantable electronic devices (CIEDs), despite their proven effectiveness in large clinical trials for a wide range of patients with arrhythmia and heart failure, are frequent targets for criticism regarding cost-efficiency and alleged overuse. Newer indications, such as sinus node...

  • Lifetime health effects and medical costs of integrated stroke services - a non-randomized controlled cluster-trial based life table approach. Baeten, Stefan A.; van Exel, N Job A.; Dirks, Maaike; Koopmanschap, Marc A.; Dippel, Diederik W. J.; Niessen, Louis W. // Cost Effectiveness & Resource Allocation;2010, Vol. 8, p21 

    Background: Economic evaluation of stroke services indicates that such services may lead to improved quality of life at affordable cost. The present study assesses lifetime health impact and cost consequences of stroke in an integrated service setting. Methods: The EDISSE study is a prospective...

  • Rotavirus Vaccine RIX4414 (Rotarixâ„¢). Plosker, Greg L. // PharmacoEconomics;2011, Vol. 29 Issue 5, p439 

    The most common cause of severe diarrhoea in infants and young children is rotavirus gastroenteritis (RVGE), which is associated with significant morbidity, healthcare resource use and direct and indirect costs in industrialized nations. The monovalent rotavirus vaccine RIX4414 (Rotarix_) is...

  • The costs of clinical trials. Fletcher, Robert H.; Fletcher, R H // JAMA: Journal of the American Medical Association;10/6/89, Vol. 262 Issue 13, p1842 

    Editorial. Focuses on the cost-effectiveness of clinical trials. Definition of fixed costs and effectiveness; Reasons why policymakers do not clamor for more spending on research; View that clinical trials are a bad investment at any price; Importance of value judgments on how to spend health...


Read the Article


Sign out of this library

Other Topics